AUTHOR=Zou Wenbo , Wang Hao , Wu Dingguo , Wu Yunyang , Zhou Kuiping , Lian Yuanshu , Chang Gengyun , Feng Yuze , Liang Jifeng , Huang Gao 

TITLE=ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer

JOURNAL=Frontiers in Endocrinology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1093042

DOI=10.3389/fendo.2023.1093042

ISSN=1664-2392

ABSTRACT=<sec><title>Introduction</title><p>Malignant pancreatic cancer has poor long-term survival. Increasing evidence shows that <italic>FAM83A</italic> (family with sequence similarity 83 member A) plays a vital role in tumorigenesis and malignant progression in some human cancer types. The present study explored the potential mechanism of <italic>FAM83A</italic> in improving the prognosis of pancreatic cancer patients.</p></sec><sec><title>Methods</title><p>Transcriptomic and clinical data from patients were obtained from The Cancer Genome Atlas while <italic>FAM83A</italic> expression was measured in tumorous pancreatic tissue compared with normal controls by quantitative real-time PCR and immunohistochemistry.</p></sec><sec><title>Results</title><p><italic>FAM83A</italic> is a vital prognostic indicator and potential oncogene in pancreatic cancer via pan-cancer analysis. <italic>In silico</italic> analysis revealed that AL049555.1/hsa-miR-129-5p axis was the pivotal upstream ncRNA- mediated pathway of <italic>FAM83A</italic> in pancreatic cancer. Furthermore, <italic>FAM83A</italic> expression was related to immune cell infiltration through vital immune-related genes including <italic>programmed cell death 1 (PDCD1)</italic>, and tumorigenesis through common mutation genes including <italic>KRAS protooncogene GTPase (KRAS)</italic>, and <italic>SMAD family member 4 (SMAD4)</italic>. In summary, ncRNA-mediated upregulation of <italic>FAM83A</italic> is associated with poor long-term survival and immune cell infiltration in pancreatic cancer.</p></sec><sec><title>Discussion</title><p><italic>FAM83A</italic> may be used as a novel survival-related and immune-related biomarker. This information suggests that <italic>FAM83A</italic> may be a novel therapeutic target for combined or individual treatment for patients with pancreatic cancer.</p></sec>